ADR Update: Entering pivotal territory
GW has initiated its first Phase III pivotal study for Epidiolex in Dravet syndrome, a highly debilitating and treatment refractory form of childhood epilepsy. This is the first of four planned Phase III trials with Epidiolex (one more in Dravet, two in Lennox-Gastaut syndrome), all due to begin in Q215. Epidiolex is a major valuation driver, so top-line data by end-2015 from the first Phase III now underway is a significant catalyst. We also look forward to further physician-led data to be presented at AAN in mid-April to highlight Epidiolex’s potential across a wide range of childhood epilepsies.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.